Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease

World Journal of Gastroenterology

Volumn 21, Issue 19, 2015, Pages 5823-5830

  Cətanə, Cristina Sorina ^a   Neagoe, Ioana Berindan ^a   Cozma, Vasile ^b   Magdaş, Cristian ^b   Təbəran, Flaviu ^b   Dumitraşcu, Dan Lucian ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

Author keywords

Crohn's disease; Cytokines; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CALGRANULIN; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 23; MICRORNA; MONOCLONAL ANTIBODY; AUTACOID; GENETIC MARKER;

ARTICLE; ENTERITIS; GENETIC CORRELATION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PATHOGENESIS; ANIMAL; DISEASE MODEL; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE; METABOLISM; PHENOTYPE; SIGNAL TRANSDUCTION; TH17 CELL;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-17; INTERLEUKIN-23; INTESTINES; PHENOTYPE; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84929626969     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i19.5823     Document Type: Article

References (52)

1. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 2012;3:107 [PMID: 22586430 DOI: 10.3389/fimmu.2012.00107]
2. Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am 2007;87:575-585 [PMID: 17560413]
3. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014;13:3-10 [PMID: 23774107 DOI: 10.1016/j.autrev. 2013.06.004]
4. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-317 [PMID: 21677747 DOI: 10.1038/nature10209]
5. Nunes T, Fiorino G, Danese S, Sans M. Familial aggregation in inflammatory bowel disease: is it genes or environment? World J Gastroenterol 2011;17:2715-2722 [PMID: 21734779 DOI: 10.3748/wjg.v17.i22.2715]
6. Danese S. What's hot in inflammatory bowel disease in 2011? World J Gastroenterol 2011;17:545-546 [PMID: 21350702 DOI: 10.3748/wjg.v17.i5.545]
7. Scaldaferri F, Correale C, Gasbarrini A, Danese S. Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? World J Gastroenterol 2010;16:2616-2625 [PMID: 20518083 DOI: 10.3748/wjg.v16.i21.2616]
8. Citani CS, Berindan-Neagoe I. Aging and immunity. Age related changes in immunological, biochemical and genetic markers. Saarbrucken: Lambert Academic Publishing, 2012
9. Bamias G, Corridoni D, Pizarro TT, Cominelli F. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 2012;59:451-459 [PMID: 22795953 DOI: 10.1016/j.cyto.2012.06.014]
10. Hansen R, Thomson JM, El-Omar EM, Hold GL. The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol 2010;45:266-276 [PMID: 20076977 DOI: 10.1007/s00535-009-0191-y]
11. Galvez J. Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN Inflamm 2014;2014:928461 [PMID: 25101191 DOI: 10.1155/2014/928461]
12. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology 2008;125:145-153 [PMID: 18798918 DOI: 10.1111/j.1365-2567.2008]
13. Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology 2011;140:1838-1846 [PMID: 21530750 DOI: 10.1053/j.gastro.2011.02.014]
14. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357 [PMID: 2419430]
15. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933-944 [PMID: 12461566 DOI: 10.1038/nri954]
16. Jelley-Gibbs DM, Strutt TM, McKinstry KK, Swain SL. Influencing the fates of CD4 T cells on the path to memory: lessons from influenza. Immunol Cell Biol 2008;86:343-352 [PMID: 18362946 DOI: 10.1038/icb.2008.13]
17. Geremia A, Jewell DP. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2012;6:223-237 [PMID: 22375527 DOI: 10.1586/egh.11.107]
18. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008;8:337-348 [PMID: 18408735 DOI: 10.1038/nri2295]
19. Bettelli E, Oukka M, Kuchroo VK. T (H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-350 [PMID: 17375096]
20. Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn's disease. Discov Med 2012;14:253-262 [PMID: 23114581]
21. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT. Late developmental plasticity in the T helper 17 lineage. Immunity 2009;30:92-107 [PMID: 19119024 DOI: 10.1016/j.immuni.2008.11.005]
22. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-1861 [PMID: 17635957]
23. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-1767 [PMID: 21530742 DOI: 10.1053/j.gastro.2011.02.016]
24. Liu Z, Yadav PK, Xu X, Su J, Chen C, Tang M, Lin H, Yu J, Qian J, Yang PC, Wang X. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J Leukoc Biol 2011;89:597-606
25. Sallusto F, Zielinski CE, Lanzavecchia A. Human Th17 subsets. Eur J Immunol 2012;42:2215-2220 [PMID: 22949319 DOI: 10.1002/eji.201242741]
26. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, Powrie F. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010;33:279-288 [PMID: 20732640 DOI: 10.1016/j.immuni.2010.08.010]
27. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23 [PMID: 16290228]
28. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol 2010;11:674-680 [PMID: 20644573 DOI: 10.1038/ni.1899]
29. Ueno A, Jijon H, Chan R, Ford K, Hirota C, Kaplan GG, Beck PL, Iacucci M, Fort Gasia M, Barkema HW, Panaccione R, Ghosh S. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4 T cells and defective suppressive function of circulating Foxp3 regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis 2013;19:2522-2534 [DOI: 10.1097/MIB.0b013e3182a85709]
30. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140:1704-1712 [PMID: 21530736 DOI: 10.1053/j.gastro.2011.02.046]
31. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, Khawaja SA, Bagnall R, Burke DA, Todhunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell DP, Satsangi J, Mansfield JC, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-832 [PMID: 17554261]
32. Kim SW, Kim ES, Moon CM, Park JJ, Kim TI, Kim WH, Cheon JH. Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease. Gut 2011;60:1527-1536 [PMID: 21672939 DOI: 10.1136/gut.2011.238477]
33. Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Göke B, Glas J, Ochsenkühn T, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010;105:1811-1819 [PMID: 20197757 DOI: 10.1038/ajg.2010.95]
34. Van De Logt F, Day AS. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease. J Dig Dis 2013;14:62-67 [PMID: 23146044 DOI: 10.1111/1751-2980.12012]
35. Lu Y, Zhou L, Liu L, Feng Y, Lu L, Ren X, Dong X, Sang W. Serum omentin-1 as a disease activity marker for Crohn's disease. Dis Markers 2014;2014:162517 [PMID: 24659847 DOI: 10.1155/2014/162517]
36. Grad C, David L, Portincasa P, Dumitraşcu DL. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease. Rom J Intern Med 2012;50:3-6 [PMID: 22788087]
37. Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers 2014;2014:710915 [PMID: 24963213 DOI: 10.1155/2014/710915]
38. Husain N, Tokoro K, Popov JM, Naides SJ, Kwasny MJ, Buchman AL. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2013;47:246-251 [PMID: 23269308 DOI: 10.1097/MCG.0b013e3182582cdb]
39. Iborra M, Bernuzzi F, Correale C, Vetrano S, Fiorino G, Beltrán B, Marabita F, Locati M, Spinelli A, Nos P, Invernizzi P, Danese S. Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. Clin Exp Immunol 2013;173:250-258 [PMID: 23607522 DOI: 10.1111/cei.12104]
40. Lin J, Welker NC, Zhao Z, Li Y, Zhang J, Reuss SA, Zhang X, Lee H, Liu Y, Bronner MP. Novel specific microRNA biomarkers in idiopathic inflammatory bowel disease unrelated to disease activity. Mod Pathol 2014;27:602-608 [PMID: 24051693 DOI: 10.1038/modpathol.2013.152]
41. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol 2014;7:6-19 [PMID: 24084775 DOI: 10.1038/mi.2013.73]
42. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61:918-932 [PMID: 22115827 DOI: 10.1136/gutjnl-2011-300904]
43. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-1700 [PMID: 22595313 DOI: 10.1136/gutjnl-2011-301668]
44. Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, Greenbloom S. Randomized, double-blind, placebocontrolled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 2010;16:1209-1218 [PMID: 19918967 DOI: 10.1002/ibd.21159]
45. Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, Stolfi C, Cardolini I, Dottori M, Boirivant M, Pallone F, Macdonald TT, Monteleone G. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008;134:1038-1048 [PMID: 18395085 DOI: 10.1053/j.gastro.2008.01.041]
46. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, De Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG, ERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-1528 [PMID: 23075178 DOI: 10.1056/NEJMoa1203572]
47. Wedebye Schmidt EG, Larsen HL, Kristensen NN, Poulsen SS, Lynge Pedersen AM, Claesson MH, Pedersen AE. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis 2013;19:1567-1576 [PMID: 23689808 DOI: 10.1097/MIB.0b013e318286fa1c]
48. Fitzpatrick LR. Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis. Int J Inflam 2012;2012:389404 [PMID: 22506136 DOI: 10.1155/2012/389404]
49. Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 2013;7:636-643 [PMID: 23078909 DOI: 10.1016/j.crohns.2012.09.016]
50. Ray S, De Salvo C, Pizarro TT. Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis. Curr Opin Gastroenterol 2014;30:531-538 [PMID: 25255234 DOI: 10.1097/MOG.0000000000000119]
51. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999;11:648-656 [PMID: 10631550]
52. Plaza-Diaz J, Gomez-Llorente C, Fontana L, Gil A. Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World J Gastroenterol 2014;20:15632-15649 [PMID: 25400447 DOI: 10.3748/wjg.v20.i42.15632]